MA31466B1 - Derives de benzimidazole - Google Patents

Derives de benzimidazole

Info

Publication number
MA31466B1
MA31466B1 MA32454A MA32454A MA31466B1 MA 31466 B1 MA31466 B1 MA 31466B1 MA 32454 A MA32454 A MA 32454A MA 32454 A MA32454 A MA 32454A MA 31466 B1 MA31466 B1 MA 31466B1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
mammals
compounds
treatment
cell growth
Prior art date
Application number
MA32454A
Other languages
Arabic (ar)
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA31466B1 publication Critical patent/MA31466B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule i (i) ou un de ses sels pharmaceutiquement acceptables, dans laquelle r1, r2, r3a, r3b, r4, r5, x, m et n sont tels que définis dans le présent document. De tels nouveaux dérivés de benzamidazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les mammifères. L'invention concerne également un procédé d'utilisation de tels composés dans le traitement de la croissance cellulaire anormale chez les mammifères, notamment les humains, et des compositions pharmaceutiques qui contiennent de tels composés.
MA32454A 2007-06-29 2009-12-29 Derives de benzimidazole MA31466B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (1)

Publication Number Publication Date
MA31466B1 true MA31466B1 (fr) 2010-06-01

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32454A MA31466B1 (fr) 2007-06-29 2009-12-29 Derives de benzimidazole

Country Status (45)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20121010A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690953C (fr) 2007-06-29 2012-10-02 Pfizer Inc. Derives de benzamidazole
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
EA201270311A1 (ru) 2009-08-26 2012-09-28 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое производное и его применение
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118782A1 (fr) 2011-02-28 2012-09-07 Repligen Corporation Inhibiteurs de l'histone déacétylase
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012122370A2 (fr) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utiles dans le traitement de maladies
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
CN103814024B (zh) * 2011-09-26 2016-11-23 默克专利股份公司 作为溶血磷脂酸(lpa)受体拮抗剂的苄基哌啶化合物
EP2863920B1 (fr) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Dérivés de quinoline pour l'utilisation dans le traitement du cancer du sein
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
RU2665554C2 (ru) 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
EP2996689A1 (fr) * 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3286176B1 (fr) * 2015-04-24 2020-01-15 Pfizer Inc Des formes cristallines de 1-((2r,4r) -2-(1h-benzo [ d ] imidazol-2-yl ) -1-méthylpipéridin-4-yl) -3-(4-cyanophényl) urée maléate
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7792189B2 (ja) * 2019-03-29 2025-12-25 デクセリアルズ株式会社 接着剤組成物
US12668581B2 (en) 2020-01-28 2026-06-30 Assia Chemical Industries Ltd. Processes for the preparation of Glasdegib and salt thereof and solid state forms of Glasdegib maleate and process for preparation thereof
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (fr) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine -4-yl)-3-(4-cyanophényl)urée
EP4173639A4 (fr) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
CA2473892C (fr) * 2001-12-04 2010-09-21 Actelion Pharmaceuticals Ltd Nouveaux derives de quinoleines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
WO2005042497A2 (fr) 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles convenant comme modulateurs des canaux ioniques
CA2587489C (fr) * 2004-11-03 2013-12-31 Curis, Inc. Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
WO2008075196A1 (fr) 2006-12-15 2008-06-26 Pfizer Products Inc. Dérivés du benzamidazole
CA2690953C (fr) 2007-06-29 2012-10-02 Pfizer Inc. Derives de benzamidazole
EP2303275A4 (fr) 2008-06-17 2012-05-09 Univ Duke Modulateurs du récepteur smoothened
CN102203067B (zh) 2008-08-25 2014-01-15 Irm责任有限公司 Hedgehog通路调节剂

Also Published As

Publication number Publication date
HK1139658A1 (en) 2010-09-24
NZ581889A (en) 2011-05-27
CN101687841A (zh) 2010-03-31
PT2170860T (pt) 2017-01-04
ECSP099803A (es) 2010-01-29
KR20100028120A (ko) 2010-03-11
EP2170860A2 (fr) 2010-04-07
US20120157495A1 (en) 2012-06-21
CR11150A (es) 2010-02-08
AR067346A1 (es) 2009-10-07
JP2010280693A (ja) 2010-12-16
CN101687841B (zh) 2013-07-10
TWI371451B (en) 2012-09-01
ES2609258T3 (es) 2017-04-19
WO2009004427A3 (fr) 2009-06-04
FR20C1038I2 (fr) 2021-08-13
HUE030052T2 (hu) 2017-04-28
CU23847B1 (es) 2012-10-15
BRPI0813412B1 (pt) 2020-01-21
RS55395B9 (sr) 2020-01-31
DK2170860T3 (en) 2017-01-09
SI2170860T1 (sl) 2017-01-31
GT200900328A (es) 2011-08-29
NL301057I1 (nl) 2020-07-22
US20090005416A1 (en) 2009-01-01
AU2008272641A1 (en) 2009-01-08
IL202420A0 (en) 2010-06-30
MY148636A (en) 2013-05-15
HRP20161562T1 (hr) 2016-12-30
CL2008001922A1 (es) 2009-01-02
BRPI0813412A2 (pt) 2014-12-30
FR20C1038I1 (fr) 2020-10-02
US8148401B2 (en) 2012-04-03
JP2010531869A (ja) 2010-09-30
AU2008272641B2 (en) 2013-08-29
TN2009000544A1 (fr) 2011-03-31
KR101143246B1 (ko) 2012-05-18
AP2377A (en) 2012-03-07
NL301057I2 (nl) 2020-09-10
GEP20125702B (en) 2012-12-10
HN2008000974A (es) 2011-01-24
PA8785401A1 (es) 2009-01-23
CY1118650T1 (el) 2017-07-12
WO2009004427A2 (fr) 2009-01-08
CY2020028I1 (el) 2020-11-25
CY2020028I2 (el) 2020-11-25
TW200911792A (en) 2009-03-16
CO6160232A2 (es) 2010-05-20
BRPI0813412B8 (pt) 2021-05-25
ME00962B (fr) 2012-06-20
EP2170860B9 (fr) 2017-02-22
UY31164A1 (es) 2009-01-30
JP4567099B2 (ja) 2010-10-20
IL202420A (en) 2014-05-28
CA2690953C (fr) 2012-10-02
LTC2170860I2 (lt) 2022-03-10
CU20090225A7 (es) 2012-02-15
LT2170860T (lt) 2017-01-10
CA2690953A1 (fr) 2009-01-08
HRP20161562T2 (hr) 2017-04-21
EP2170860B1 (fr) 2016-11-02
RS55395B1 (sr) 2017-04-28
PL2170860T3 (pl) 2017-05-31
NO2020027I1 (no) 2020-08-11
HUS2000031I1 (hu) 2020-09-28
DK2170860T5 (en) 2017-03-20
LTPA2020528I1 (lt) 2020-09-25
AP2009005089A0 (en) 2009-12-31
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
PE20121010A1 (es) 2012-08-06
EA016888B1 (ru) 2012-08-30
HUE030052T4 (en) 2017-06-28
DOP2009000278A (es) 2009-12-31
EA200971104A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
TN2009000544A1 (fr) Derives de benzimidazole
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA29926B1 (fr) Derives de pyrazine
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
DK1678166T3 (da) Proteinkinaseinhibitorer
MA30781B1 (fr) Inhibiteur de kinase
MA29909B1 (fr) Derives de pyridazine
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
MA31373B1 (fr) Composes amino-heterocycliques
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine